Restructuring Global Liquidity: Structural Opportunities from US Defense to Yield-Bearing ETFsGlobal Report·Jul 22 at 04:18 AMDRS+0.94%REA-1.39%
Caribou Biosciences CEO joins H.C. Wainwright cell therapy conference fireside chatPUBT·Jun 29 at 07:02 AMCRBU-3.31%
Caribou Biosciences shareholders reject officer exculpation charter amendment at annual meetingPUBT·Jun 18 at 03:03 PMCRBU-3.31%
Analyst Reiterates Buy on Caribou, Citing Strong vispa-cel Data and Pivotal ANTLER-3 Upside; Price Target Maintained at $11Tip Ranks·Jun 16 at 05:16 AMCRBU-3.31%
Analyst Reiterates Buy on Caribou Biosciences, Keeps $8 Price Target After Encouraging Allo CAR-T DataTip Ranks·Jun 11 at 07:25 PMCRBU-3.31%
Caribou Biosciences: Buy Rating Reaffirmed on Advancing Allogeneic CAR-T Pipeline and EHA Data; $6 Price Target MaintainedTip Ranks·Jun 11 at 07:19 PMCRBU-3.31%
Caribou Biosciences Reports Long-Term Vispa-cel Data in Second-line Large B Cell Lymphoma at EHA 2026Unusual Whales·Jun 11 at 07:04 AMCRBU-3.31%
Caribou Biosciences Says CRISPR CAR-T Is Pivotal-Ready, CB-011 Data NearsMarket Beat·Jun 9 at 05:04 AMCRBU-3.31%
Bank of America Securities Remains a Buy on Caribou Biosciences (CRBU)Tip Ranks·May 13 at 04:39 AMCRBU-3.31%BIB-3.70%
Caribou Biosciences (NASDAQ:CRBU) Issues Quarterly Earnings ResultsMarket Beat·May 9 at 05:50 PMCRBU-3.31%BBH-1.18%
Caribou Biosciences | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 2.397 MEarnings Watch·May 7 at 10:44 PMCRBU-3.31%
Caribou Biosciences | 10-Q: FY2026 Q1 Revenue Beats Estimate at USD 2.397 MEarnings Watch·May 7 at 10:37 PMCRBU-3.31%
Caribou Biosciences (CRBU) Expected to Announce Quarterly Earnings on ThursdayMarket Beat·May 7 at 01:48 AMCRBU-3.31%FBT-3.01%
